Table 3.
Baseline Demographic and Clinical Characteristics
| INTERVENTION (N=34) | CONTROL (N=33) | P VALUE | |
|---|---|---|---|
| Age (years) | 64±6 | 63±8 | 0.58 |
| Sex (number female) | 17 | 24 | 0.08 |
| Smoking (pack-years) | 43±22 | 54±25 | 0.053 |
| BMI (kg/m2) | 29±6 | 30±7 | 0.42 |
| Number (%) of patients on oxygen | 23/34 (67%) | 23/33 (70%) | 1 |
| Oxygen (L/min) | 3.0±1.7 | 2.9±1.1 | 0.76 |
| mMRC (n) | 0.37 | ||
| 0 | 1 | 0 | |
| 1 | 5 | 3 | |
| 2 | 4 | 8 | |
| 3 | 16 | 11 | |
| 4 | 8 | 11 | |
| SGRQ total score | 59±11 | 60±12 | 0.71 |
| SF-36 | |||
| Physical component | 25±19 | 17±13 | 0.06 |
| Mental component | 66±20 | 70±17 | 0.35 |
| Long-acting beta-agonist | 28/34 (82%) | 26/33 (79%) | 0.77 |
| Inhaled corticosteroids | 29/34 (85%) | 31/33 (94%) | 0.43 |
| Long-acting anticholinergic | 22/34 (65%) | 25/33 (76%) | 0.43 |
| Short-acting beta-agonist | 34/34 (100%) | 33/33 (100%) | 1 |
| Comorbidities | |||
| DM | 3/34 (9%) | 4/33 (12%) | 0.71 |
| CAD | 7/34 (21%) | 13/33 (39%) | 0.11 |
| FVC (%) | 74±15 | 68±17 | 0.16 |
| FEV1 (%) | 31±13 | 32±15 | 0.76 |
| FEV1/FVC (%) | 34±13 | 38±13 | 0.16 |
| TLC (%) | 112±18 | 112±17 | 0.96 |
| RV (%) | 182±49 | 182±47 | 0.99 |
| DLCO (%) | 54±15 | 54±15 | 0.90 |
| pH | 7.42±0.02 | 7.42±0.02 | 0.77 |
| PaCO2 (mm Hg) | 42±7 | 45±7 | 0.29 |
| PaO2 (mm Hg) | 67±14 | 65±10 | 0.55 |
| 6MWT (min) | 262±83 | 254±96 | 0.73 |
6MWT, 6-min walk test; BMI, body mass index; CAD, coronary artery disease; DLCO, diffusing capacity for carbon monoxide; DM, diabetes mellitus; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; mMRC, Modified Medical Research Council Dyspnea Scale; PaCO2, partial pressure of carbon dioxide in blood; PaO2, partial pressure of oxygen in blood; RV, residual lung volume; SF-36, Short Form 36 Health Survey; SGRQ, St. George's Respiratory Questionnaire; TLC, total lung capacity.